| DIRECT COMPETITOR COMPARISON | |
| EMIS.OB | BMY | GSK | UGNE.OB | Industry | | Market Cap: | 37.86M | 50.99B | 108.60B | 62.16M | 73.18M | | Employees: | 20 | 35,000 | 99,003 | 103 | 38 | | Qtrly Rev Growth (yoy): | N/A | 4.40% | 14.90% | -46.30% | 3.00% | | Revenue (ttm): | 5.00K | 21.14B | 44.15B | 15.07M | 17.49M | | Gross Margin (ttm): | 100.00% | 72.39% | 76.27% | 78.55% | 63.53% | | EBITDA (ttm): | -15.43M | 6.32B | 17.40B | -10.52M | -6.12M | | Oper Margins (ttm): | -322,640.00% | 26.65% | 34.30% | -74.58% | -3.79% | | Net Income (ttm): | -21.34M | 3.79B | 7.93B | -14.91M | N/A | | EPS (ttm): | -0.673 | 1.933 | 3.11 | -0.165 | -0.19 | | P/E (ttm): | N/A | 13.32 | 13.77 | N/A | 16.72 | | PEG (5 yr expected): | N/A | 5.12 | 3 | N/A | 1.34 | | P/S (ttm): | 7446.39 | 2.43 | 2.46 | 4.37 | 3.33 |
|
| BMY = Bristol-Myers Squibb Co. | | GSK = GlaxoSmithKline plc | | UGNE.OB = Unigene Laboratories Inc. | | Industry = Drug Delivery | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.75 | -1.95% | 56.43B | 12.16 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 49.43 | 1.15% | 14.30B | 16.54 | | Genzyme Corp. | GENZ | 49.25 | -1.46% | 13.07B | 28.08 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 45.31 | -3.51% | 40.78B | 17.52 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.49 | -0.25% | 9.18B | 1050.82 | | Teva Pharmaceutical Industries Limited | TEVA | 53.20 | -0.54% | 46.87B | 48.67 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 38.36 | -0.75% | 4.07B | 19.77 | | King Pharmaceuticals Inc. | KG | 11.87 | 0.25% | 2.95B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 19.04 | 1.44% | 5.82B | 116.81 | | Pfizer Inc. | PFE | 18.29 | -0.60% | 147.59B | 15.19 | | Johnson & Johnson | JNJ | 64.74 | -0.34% | 178.62B | 14.14 | | GlaxoSmithKline plc | GSK | 42.84 | -0.16% | 108.60B | 13.77 | | Sanofi-Aventis | SNY | 38.66 | -0.26% | 100.95B | N/A | | Novartis AG | NVS | 53.76 | -0.83% | 122.10B | 16.10 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 40.85 | -0.37% | N/A | N/A | | AstraZeneca plc | AZN | 46.10 | 0.70% | 66.84B | 9.26 | | Abbott Laboratories | ABT | 53.99 | 0.39% | 83.51B | 14.63 | | Bristol-Myers Squibb Co. | BMY | 25.74 | -0.85% | 50.99B | 13.32 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BMY | | 8 High-Quality Dividend Stocks
Tue 5:53pm -
at Seeking Alpha | | • | BMY | | Ciena Out of S&P 500
Tue 4:20pm -
Zacks.com | | • | GSK | | Pfizer in China, AIDS Drugs in Africa, Vaccine Recall in U.S.
Tue 3:38pm -
at The Wall Street Journal Online | | • | GSK | | US swine flu response hurt by spending cut -report
Tue 2:59pm -
at Reuters | | • | GSK | | Progress On AIDS Plan
Tue 1:42pm -
at Forbes.com | | • | BMY | | It's Nice to Have Friends With Cash
Tue 1:10pm -
at Motley Fool | | • | GSK | | Which Doctors Are Getting Paid By Glaxo, Lilly and Merck?
Tue 12:55pm -
at The Wall Street Journal Online | | • | BMY | | HIV pool adds to pressure on drug groups
Tue 12:15pm -
at FT.com | | • | BMY | | Morning Movers: Bristol Myers Off On Short Call, WellPoint Rising, Financials Weak
Tue 12:10pm -
at Barrons.com | | • | BMY | | [$$] Investing Without the Help of a Rising Tide
Tue 6:30am -
at Barrons.com | | • | BMY | | UPDATE - Pfizer lifts dividend, yield closer to rivals
Mon 5:25pm -
at Reuters | | • | BMY | | Pfizer, General Mills Raise Dividend
Mon 5:04pm -
at Barrons.com | | • | BMY | | Exxon Mobil, Bristol-Myers Squibb: Money Flow Leaders (XOM, BMY)
Mon 4:49pm -
at The Wall Street Journal Online | | • | GSK | | Bloomberg: GSK has paid $1B in Paxil lawsuits
Mon 3:05pm -
at bizjournals.com | | • | GSK | | Big Pharma and the Profit Problem of Rare Diseases
Mon 2:30pm -
at Minyanville.com | | • | GSK | | Almost $280 Billion In Medicaid Allocated For The Elderly And Disabled: Former Lehman Brothers Analyst Sees Huge Opportunity For Sector Stocks
Mon 11:51am -
Wall Street Transcript | | • | UGNE.OB | | Biotech's Latest Failed Trials, Missed Targets
Mon 4:22am -
at Seeking Alpha | | • | UGNE.OB | | UNIGENE LABORATORIES INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Financial Statements
Fri, Dec 11 -
EDGAR Online | | • | UGNE.OB | | Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies for Osteoporosis and Osteoarthritis
Thu, Dec 10 -
Business Wire | | • | UGNE.OB | | Unigene Announces Significant Cost Savings and Corporate Restructuring
Wed, Dec 9 -
Business Wire | | • | UGNE.OB | | UNIGENE LABORATORIES INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | UGNE.OB | | UNIGENE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Mon, Nov 9 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.47% Nasdaq 
0.02 (1.69%) 
Competitors
